Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

The aim of the present study was to determine whether modifying the local bone environment with osteoprotegerin (OPG), the soluble decoy receptor for receptor activator of nuclear factor-kappaB (RANK) ligand, could affect tumor burden and survival in the 5T33MM murine model of multiple myeloma. Trea...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän:	Vanderkerken, K, De Leenheer, E, Shipman, C, Asosingh, K, Willems, A, Van Camp, B, Croucher, P
Materialtyp:	Journal article
Språk:	English
Publicerad:	2003

Liknande verk

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
av: Croucher, P, et al.
Publicerad: (2003)

Osteoprotegerin and the development of myeloma bone disease
av: Croucher, P, et al.
Publicerad: (2004)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
av: Croucher, P, et al.
Publicerad: (2001)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
av: De Leenheer, E, et al.
Publicerad: (2004)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
av: Croucher, P, et al.
Publicerad: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
av: Croucher, P, et al.
Publicerad: (2000)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
av: Shipman, C, et al.
Publicerad: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
av: Croucher, P, et al.
Publicerad: (2001)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
av: Croucher, P, et al.
Publicerad: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
av: Croucher, P, et al.
Publicerad: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
av: Shipman, C, et al.
Publicerad: (2000)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
av: De Leenheer, E, et al.
Publicerad: (2002)

Bisphosphonates and in vivo models of multiple myeloma - Reply
av: Shipman, C, et al.
Publicerad: (2001)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
av: Shipman, C, et al.
Publicerad: (2002)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
av: Shipman, C, et al.
Publicerad: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
av: Shipman, C, et al.
Publicerad: (2003)

Bisphosphonates--mechanisms of action in multiple myeloma.
av: Shipman, C, et al.
Publicerad: (2000)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
av: Shipman, C, et al.
Publicerad: (2002)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
av: Mueller, G, et al.
Publicerad: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
av: Mueller, G, et al.
Publicerad: (2004)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
av: Croucher, P, et al.
Publicerad: (2002)

Role of osteoprotegerin (OPG) in cancer.
av: Holen, I, et al.
Publicerad: (2006)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
av: Holen, I, et al.
Publicerad: (2002)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
av: Clive Henry Buckle, et al.
Publicerad: (2012-01-01)

Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma
av: Jerome T. Higgs, et al.
Publicerad: (2017-11-01)

Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma
av: Jo Caers, et al.
Publicerad: (2010-01-01)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
av: Holen, I, et al.
Publicerad: (2002)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
av: Liesbeth Bieghs, et al.
Publicerad: (2010-01-01)

The role of osteoprotegerin in breast and prostate cancer
av: Holen, I, et al.
Publicerad: (2002)

Pangasius djambal gelatin increases osteoprotegerin, decreases RANK and RANKL after tooth extraction in vivo
av: Fredy Mardiyantoro, et al.
Publicerad: (2023-12-01)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
av: Edwards, C, et al.
Publicerad: (2007)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
av: Eaton, C, et al.
Publicerad: (2004)

The iron chelator deferoxamine decreases myeloma cell survival
av: Feifei Yang, et al.
Publicerad: (2021-01-01)

Anti-tumour activity of bisphosphonates in human myeloma cells.
av: Shipman, C, et al.
Publicerad: (1998)

Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment
av: K. Sfiridaki, et al.
Publicerad: (2011-01-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
av: Locklin, R, et al.
Publicerad: (2005)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
av: Shipman, C, et al.
Publicerad: (1997)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
av: Shipman, C, et al.
Publicerad: (2000)

Meiosis decreases recombination load; Mitosis increases recombination load
av: Root Gorelick, et al.
Publicerad: (2018-05-01)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
av: Shipman, C, et al.
Publicerad: (1998)